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Abstract 
Fibroblast growth factor receptor 3 (FGFR3), highly conserved in both humans and murine, is 
one of key tyrosine kinase receptors for FGF. FGFR3 is expressed in different tissues, in-
cluding cartilage, brain, kidney, and intestine at different development stages. Conventional 
knockout of Fgfr3 alleles leads to short life span, and overgrowth of bone. In clinic, human 
FGFR3 mutations are responsible for three different types of chondrodysplasia syndromes 
including achondroplasia (ACH), hypochondroplasia (HCH) and thanatophoric dysplasia 
(TD). For better understanding of the roles of FGFR3 in different tissues at different stages of 
development and in pathological conditions, we generated Fgfr3 conditional knockout mice in 
which loxp sites flank exons 9-10 in the Fgfr3 allele. We also demonstrated that Cre-mediated 
recombination using Col2a1-Cre, a Cre line expressed in chondrocyte during bone develop-
ment, results in specific deletion of the gene in tissues containing cartilage. This animal model 
will be useful to study distinct roles of FGFR3 in different tissues at different ages.  
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Introduction 
Fibroblast growth factor receptor 3 (FGFR3) is 
one of the four membrane-spanning receptor tyrosine 
kinases that serve as high affinity receptors for mul-
tiple fibroblast growth factors [1]. Fgfr3 is mainly ex-
pressed in cartilage, and negatively regulates bone 
growth [2, 3]. Gain-of-function mutations in human 
FGFR3 lead to three types of chondrodysplasia syn-
dromes including achondroplasia (ACH), hypochon-
droplasia (HCH) and thanatophoric dysplasia (TD) 
[4-9]. Recently partial loss-of-function mutation of 
FGFR3 was found to cause camptodactyly, tall sta-
ture, scoliosis, and hearing loss (CATSHL) syndrome 
[10]. The expression of Fgfr3 is also detected in other 
organs such as kidney, intestine, brain, spinal cord 
and so on [11-14], which indicates that FGFR3 could 
regulate the development and physiological and pa-
thological functions of these cells.  
To explore the roles of FGFR3 in development 
and diseases, mouse models with genetic modifica-
tion of FGFR3 have been generated [1-3, 15-18]. Deng 
and Colvin, etc have independently generated con-
ventional  Fgfr3 knock out mouse models [2, 3] or Int. J. Biol. Sci. 2010, 6 
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model with deficiency in a specific isoform [18], which 
have been used to study the role of FGFR3 in a variety 
of developmental and disease processes [2, 19-21]. In 
these conventional knock out mice, Fgfr3 is disrupted 
in all cells, which prevents the effort for further stud-
ying of the role of FGFR3 in specific types of cells and 
their corresponding cellular and molecular mechan-
isms. For example, it is difficult to know if the de-
creased bone mass in Fgfr3 null mice [20] is seconda-
rily related to the altered chondrogenesis and/or di-
rectly related to changes in osteogenesis [2, 3], because 
both chondrogenesis and osteogenesis were found 
changed in Fgfr3 knock out mice [16, 20]. Further-
more, in certain genetic background, the lifespan of 
Fgfr3 null mice is relatively shorter than their normal 
littermates [20], which prevents us from studying the 
role of FGFR3 in later development and diseases in 
adult stages such as aging related diseases. In addi-
tion, in conventional Fgfr3 knock out mouse models, 
the morphology structure of tissue has significant 
changes during early development stage. It is im-
possible to exclude the potential role of already 
changed tissue in the pathogenesis of regeneration 
and healing. To overcome these disadvantages, we 
have generated a Fgfr3 conditional null allele, the 
Fgfr3flox allele. 
The mouse Fgfr3 gene contains 19 exons and 
spans about 25 kb on chromosome 5. The protein 
product of FGFR3 is encoded by exons 2-18 [22]. As 
for FGFR3, alternative splicing of the second half of 
the third Ig domain produces two isoforms, IIIb (en-
coded by exons 7 and 8) and IIIc (encoded by exons 7 
and 9) [23]. The transmembrane domain is encoded by 
exon 10. Deletion of exons 9 and 10 is expected to 
cause loss of function of both IIIb and IIIc isoform of 
FGFR3. 
Materials and Methods  
Generation of the Fgf3floxneo allele 
The targeting vector was constructed using Fgfr3 
genomic DNA isolated previously [3]. The ploxPneo 
vector was described previously [24]. Briefly, in the 
targeting vector, the 3.8-kb fragment including intron 
10 to part of exon 19 was inserted into ploxPneo vector 
using Not I and Sma I to generate the 3’ homology 
recombination arm. The 5’ homology recombination 
arm in the targeting vector was generated by inserting 
the 5.5-kb Cla I-Xba I fragment including part of intron 
2 to intron 10 and the third Loxp was inserted into 
intron 8 of the Fgfr3  locus. The finished targeting 
construct, Fgfr3floxneo, is shown in Figure 1a.  
Electroporation of ES cells and generation of germline 
chimeras 
TC1 embryonic stem (ES) cells [3] were trans-
fected with Not I-digested  ploxPneoFgfr3 by electro-
poration and selected using G418 and 
-(2-deoxy-2-fluoro-β-D-avabinofuranosyl-S-iodouracil 
(FIAU). The homologous recombination events within 
the Fgfr3 locus from both G418- and FIAU-resistant ES 
clones were analyzed by Southern blot using the 5’ 
external probe with Spe I-digested DNA. The 5′ probe 
is a 1.9-kb BamH I-Sac I fragment specific to the Fgfr3 
sequence. The third Loxp was identified by PCR using 
primer p1 (5’-GATGCCTCAACAATACTGGTAG 
CCC-3’) and p2  (5’-CCAGACAGATGGATGGACA 
GGAA-3’). Cells heterozygous for the targeted muta-
tion were microinjected into blastocysts from C57/B6 
mice to obtain germ-line transmission following 
standard procedures.  
Genotype analysis 
The chimeric males were bred to C57BL/6 fe-
males, and F1 agouti offspring were analyzed by PCR 
for the presence of the Fgfr3floxneo allele. Genotypes of 
the mice bearing the Fgfr3neofloxed, Fgfr3flox, Fgfr3null and 
wild-type allele were determined by PCR analysis as 
illustrated in Figure 2 and 3. The primers are p3 
(5’-GCTCCCTGTCCTGCCTCGTG-3’), p4(5’-CAGCT 
CATTCCTCCCACTCATGAT-3’) and p5 
(5’-TGTAAAAGGGGTGGGGTGGTAG-3’). 
Skeletal preparation and histology. 
Mice at P15 were sacrificed. The femurs were 
fixed overnight in 4% paraformaldehyde at 4°C and 
rinsed in PBS and decalcified in 15% EDTA (pH 7.4) 
for 10-15 days before embedding in paraffin as de-
scribed previously. Six-micron thick sections were 
used for H.&E. staining. High-resolution X-ray of femurs 
from 3-month-old mice were obtained using a Faxitron 
MX20. 
RNA extraction and RT-PCR 
RNA was extracted from brain of mice using 
Trizol (Invitrogen) reagent according to the manu-
facturer’s instructions. Single strand cDNA was syn-
thesized from 1 μg of total RNA using RNA reverse 
transcriptase kit (Takara). The mRNA level of Fgfr3 
was detected by primer FGFR3-F(5’-CCACCGA 
CAAGGAGCTAGAGG-3’) and FGFR3-R 
(5’-CGGTGACAGGCTTGGCAGTA-3’). The β-actin 
gene detected by primer β-actin-F 
(5’-TTGTTACCAACTGGGACGACATGG-3’) and 
β-actin-R (5’-GATCTTGATCTTCATGGTGCTAGG 
-3’) was an internal control.  
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Figure 1. Generation of the Fgfr3
floxneo allele. (a) Strategy for generating the Fgfr3 targeting vector and Fgfr3
floxneo (targeted) 
allele. Blue boxes represent exons. The 5’ external probes for Southern Blot is indicated by thick lines. The predicted length 
of Southern fragments are indicated with double arrow lines. Cl, Cla I; No, Not I; Sm, Sma I; Sp, Spe I; Xb, Xba I; Hp, Hpa I; 
p, primer. (b) Targeted events were identified by Southern analysis of Spe I- digested genomic ES cell DNAs with a 5’flanking 
probe. (c) The third Loxp in targeted allele was confirmed by PCR. 
 
 
 
Figure 2. Generation of 
Fgfr3
floxneo/floxneo mice. (a) Map of 
Fgfr3
floxneo allele. The position 
of primers was marked in the 
map. (b) Genotype of 
Fgfr3
floxneo/floxneo mice was iden-
tified by PCR (primer p1, p2, 
p3 and p4). (c) There is no 
expression of Fgfr3 in 
Fgfr3
floxneo/floxneo mice (d) 
Fgfr3
floxneo/floxneo mice showed 
kinky tails, which is also found 
in Fgfr3 knock out mice. (e) 
Increased expansion of pro-
liferating and hypertrophic 
chondrocytes in the growth 
plate in Fgfr3
floxneo/floxneo mice on 
P15. Int. J. Biol. Sci. 2010, 6 
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Figure 3. Validation of exons 9-10 and neo gene in Fgfr3
floxneo alleles deleted by Cre recombinase. (a) Mice containing Fgfr3
floxneo 
alleles were crossed with EIIa-Cre transgenic mice resulting in three kinds of deletion between three Loxp sites (b-d). Position 
of primers was also marked. (b) Primer p1 and p5 amplify fragments of 390 bp from Fgfr3
null allele with deletion exons 9-10 
and neo between Loxp1 and 3 (1/3), no amplification for the wild type (WT). (c) Primer p1 and p4 amplify fragments of 408 
bp from Fgfr3
neofloxed allele with deletion exons 9-10 between Loxp2 and 3 (2/3), no amplification for WT. (d) Primer p3 and p5 
amplified fragments of 320 bp from Fgfr3
flox allele with deletion neo between Loxp1 and 2 (1/2), but only 260bp from WT. n, 
Fgfr3
null allele; nf, Fgfr3
neofloxed allele; f, Fgfr3
flox allele; w, wild type. 
 
Results and Discussion 
To construct the Fgfr3floxneo allele, we have made a 
targeting vector that contains two Loxp sites flanking 
the entire exons 9 and 10. In this way, existence of Cre 
recombinase would lead to deletion of exons 9 and 10, 
and subsequent inactivation of FGFR3. We inserted a 
5.5-kb fragment including exons 3-10 and the third 
Loxp (located in intron 8) into ploxPneo vector [24] as 
the 5’ homology recombination arm, then put a 3.8-kb 
fragment containing exons 10 to 19 into ploxPneo to 
form 3’ homology recombination arm (Fig. 1a). The 
Not I-linearized targeting vector Fgfr3floxneo was trans-
fected into TC1 ES cells by electroporation. Two tar-
geted ES clones were detected by Southern blot using 
a 5’ flanking external probe (Fig. 1a and b). The third 
Loxp in the ES clones was identified by PCR (Fig. 1a 
and c), which confirmed that Fgfr3floxneo allele in the 
two targeted ES clones containing the third Loxp. 
These two positive ES clones were microinjected into 
blastocysts harvested from C57/BL6 mice according 
to standard protocols.  
We first assessed if the recombination of Fgfr3 in 
mice is correct. Since we previously found in the 
Fgfr3neoG369C/+ mice that the presence of Neomycin gene 
(neo) at the same site of intron 10 blocked the normal 
splicing of the Fgfr3  mRNA, and homozygous 
Fgfr3neoG369C/neoG369C mice showed phenotypes similar 
to those of Fgfr3-null (Fgfr3-/-) mice [16]. We generated 
Fgfr3floxneo/floxneo mice by crossing Fgfr3floxneo heterozyg-
ous mice. PCR was used to identify Fgfr3floxneo/floxneo 
mice (Fig. 2a and b). RT-PCR analysis revealed that 
there was no Fgfr3 expression in Fgfr3floxneo/floxneo mice 
(Fig. 2c). We also found that Fgfr3floxneo/floxneo mice in-
deed showed skeleton phenotype including crooked 
tail and increased height of growth plates (Fig. 2d and 
e), which is similar to the phenotype of Fgfr3-/- mice [2, 
3]. These results indirectly demonstrated the correct 
recombination of the targeting construct.  
To test whether neo gene and exons 9-10 in 
Fgfr3floxneo allele can be deleted by the Cre recombinase, 
heterozygous (Fgfr3floxneo/+)  mice were crossed with 
EIIa-Cre transgenic mice that express Cre recombinase 
in germline [25, 26]. The offspring were identified by 
PCR with primers shown in Figure 3a. As expected, 
we found that this crossing breeding generated three 
types of alleles due to Cre-mediated recombination 
among three Loxp sites. A 390bp fragment was ampli-
fied from Fgfr3null allele with deletion of neo gene and 
exons 9-10 between Loxp1 and Loxp3 (confirmed by 
sequencing) (Fig. 3b). Fgfr3neofloxed allele with deletion 
of exons 9-10 was detected by producing an amplified 
408bp fragment (Fig. 3c). The PCR-amplified 320 
fragment indicated the excision of the neo gene, which Int. J. Biol. Sci. 2010, 6 
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produced a Fgfr3flox allele (conditional knockout allele) 
in Fgfr3flox/+ heterozygous mice (Fig. 3d). 
To further determine the correction of Fgfr3 re-
combination in mice, we generated homozygous Fgfr3 
null mice. RT-PCR analysis showed that there was no 
expression of Fgfr3 in the brain (Fig. 4a). These mice 
showed increased length of long bone and decreased 
bone mineral density (Fig. 4b and c), which is also 
similar to the phenotypes of Fgfr3 knock out mice [3, 
20]. Finally we crossed the Fgfr3flox/+ mice with mice 
that carry a Col2a1-Cre transgene to assess the activity 
of Fgfr3 conditional knockout allele. The result indi-
cated that the Cre-mediated deletion occurs in several 
tissues that contain cartilage, including the tail, and 
knee joint, but not in other tissues where the 
Col2a1-Cre transgene is not expressed, such as the 
lung, liver, and spleen (Fig. 4d). These data indicate 
that the Fgfr3flox allele can be recombined to delete 
exons 9-10 in a tissue-specific fashion, thus the Fgfr3 
conditional mouse model should be very useful for 
studying  Fgfr3 functions during later stages of de-
velopment. 
 
 
Figure 4. Identification of Fgfr3 null mice and validation of Fgfr3 conditional knockout allele. (a) There was no expression of 
Fgfr3 in brain RNA of Fgfr3 null mice (homozygous mice with both exons 9-10 and neo deleted in Fgfr3). (b) The length of 
femur in 3-month-old Fgfr3 null mice was longer than that in wild-type mice. (c) X-ray analysis showed increased length and 
decreased bone mineral density of femur from Fgfr3 null mice (Arrows). (d) Tissue-specific inactivation of the Fgfr3 condi-
tional allele by a Col2a1-Cre transgene in tissues containing cartilage was revealed by PCR analysis using primer pair p3/p5, 
which amplifies about 320 bp from the unrecombined allele, and primer pair p1/p5, which amplifies about 390 bp from the 
recombined allele. 
 
Conclusion 
    The results indicate that we successfully gen-
erated a mouse model for conditional deletion of 
Fgfr3, which will help to explore the role of FGFR3 in 
development and the related skeletal diseases.  
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